Elanco Animal Health Stock (NYSE:ELAN)
Previous Close
$22.87
52W Range
$13.16 - $27.72
50D Avg
$22.88
200D Avg
$22.47
Market Cap
$12.01B
Avg Vol (3M)
$6.19M
Beta
1.70
Div Yield
-
ELAN Company Profile
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
ELAN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 22 |
|---|---|---|---|
| Contract Manufacturing | $53.00M | $46.00M | $54.00M |
| Farm Animal | $2.36B | $2.25B | $2.22B |
| Pet Health | $2.30B | $2.14B | $2.14B |
| Poultry | $858.00M | $796.00M | $716.00M |
| Swine | $379.00M | $366.00M | $384.00M |
| Cattle | $1.13B | $1.01B | $944.00M |
Fiscal year ends in Dec 25 | Currency in USD